Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 2
2016 2
2017 2
2018 3
2019 3
2021 4
2022 5
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: vandemeulebroecke m. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Among authors: vandemeulebroecke m. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
The stratified win ratio.
Dong G, Qiu J, Wang D, Vandemeulebroecke M. Dong G, et al. Among authors: vandemeulebroecke m. J Biopharm Stat. 2018;28(4):778-796. doi: 10.1080/10543406.2017.1397007. Epub 2017 Nov 27. J Biopharm Stat. 2018. PMID: 29172988
Effective Visual Communication for the Quantitative Scientist.
Vandemeulebroecke M, Baillie M, Margolskee A, Magnusson B. Vandemeulebroecke M, et al. CPT Pharmacometrics Syst Pharmacol. 2019 Oct;8(10):705-719. doi: 10.1002/psp4.12455. Epub 2019 Aug 30. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31329354 Free PMC article.
Win odds: An adaptation of the win ratio to include ties.
Brunner E, Vandemeulebroecke M, Mütze T. Brunner E, et al. Among authors: vandemeulebroecke m. Stat Med. 2021 Jun 30;40(14):3367-3384. doi: 10.1002/sim.8967. Epub 2021 Apr 16. Stat Med. 2021. PMID: 33860957
25 results